» Articles » PMID: 10562283

Comparative Analysis of P73 and P53 Regulation and Effector Functions

Overview
Journal J Cell Biol
Specialty Cell Biology
Date 1999 Nov 24
PMID 10562283
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

p53 is mutated in approximately 50% of human cancers, whereas mutations of the related p73 gene are rare. p73 can activate p53-responsive promoters and induce apoptosis when overexpressed in certain p53-deficient tumor cells. We show that p73 isoforms, p73alpha and p73beta, can each induce permanent growth arrest with markers of replicative senescence when overexpressed in a tetracycline-regulatable manner in human cancer cells lacking functional p53. Human homologue of mouse double minute 2 gene product (hMDM2), but not an NH(2)-terminal deletion mutant, coimmunoprecipitated with p73alpha or p73beta, and inhibited p73 transcriptional activity as with p53. In contrast to p53, ectopically expressed hemagglutinin (HA)-tagged p73 proteins were not stabilized by treatment with several DNA damaging agents. Furthermore, unlike normal p53, which increases in response to DNA damage due to enhanced protein stability in MCF7 cells, endogenous p73 protein levels were not increased in these cells under the same conditions. Thus, although p73 has an ability, comparable to that of p53, to suppress tumor cell growth in p53-deficient cells, p73 induction is regulated differently from p53. These findings suggest that the selective pressures for p53 rather than p73 inactivation in tumors may reflect their differential responses to stresses such as DNA damage, rather than their capacities to induce permanent growth arrest or apoptosis programs.

Citing Articles

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.

Gunaratne P, Pan Y, Rao A, Lin C, Hernandez-Herrera A, Liang K Cancer. 2019; 125(14):2409-2422.

PMID: 31012964 PMC: 6617807. DOI: 10.1002/cncr.32053.


MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function.

Wu H, Leng R Oncotarget. 2015; 6(25):21479-92.

PMID: 26025930 PMC: 4673280. DOI: 10.18632/oncotarget.4086.


Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.

Puri N, Pitman R, Mulnix R, Erickson T, Iness A, Vitali C Cancer Lett. 2013; 343(1):14-23.

PMID: 24041868 PMC: 5839143. DOI: 10.1016/j.canlet.2013.09.010.


Regulatory feedback loop between TP73 and TRIM32.

Gonzalez-Cano L, Hillje A, Fuertes-Alvarez S, Marques M, Blanch A, Ian R Cell Death Dis. 2013; 4:e704.

PMID: 23828567 PMC: 3730401. DOI: 10.1038/cddis.2013.224.


Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.

Gottschalk B, Klein A Mol Cell Biochem. 2013; 379(1-2):213-27.

PMID: 23564067 DOI: 10.1007/s11010-013-1643-5.


References
1.
Werness B, Levine A, Howley P . Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248(4951):76-9. DOI: 10.1126/science.2157286. View

2.
Hollstein M, Rice K, Greenblatt M, Soussi T, Fuchs R, Sorlie T . Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994; 22(17):3551-5. PMC: 308317. View

3.
Yew P, Berk A . Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 1992; 357(6373):82-5. DOI: 10.1038/357082a0. View

4.
Gossen M, Bujard H . Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992; 89(12):5547-51. PMC: 49329. DOI: 10.1073/pnas.89.12.5547. View

5.
Momand J, Zambetti G, Olson D, George D, Levine A . The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69(7):1237-45. DOI: 10.1016/0092-8674(92)90644-r. View